Energy homeostasis deregulation is attenuated by TUDCA treatment in streptozotocin-induced Alzheimer’s disease mice model

• Published in: Scientific reports Vol. 11; no. 1; p. 18114
• Main Authors: Zangerolamo, Lucas, Solon, Carina, Soares, Gabriela M., Engel, Daiane F., Velloso, Licio A., Boschero, Antonio C., Carneiro, Everardo M., Barbosa, Helena Cristina L.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13-09-2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/378; 631/378/340; 631/443; 631/443/319; Adipose tissue; Adiposity; Alzheimer Disease - drug therapy; Alzheimer Disease - etiology; Alzheimer Disease - metabolism; Alzheimer Disease - pathology; Alzheimer's disease; Animal models; Animals; Appetite; Biomarkers; Body Weight; Cognitive ability; Dementia disorders; Deregulation; Disease Management; Disease Models, Animal; Energy; Energy balance; Energy expenditure; Energy metabolism; Energy Metabolism - drug effects; Food; Food intake; Gene Expression; Homeostasis; Humanities and Social Sciences; Hypothalamus; Immunohistochemistry; Inflammation; Inflammation Mediators - blood; Inflammation Mediators - metabolism; Janus kinase 2; Leptin; Leptin - metabolism; Male; Metabolic disorders; Metabolism; Mice; multidisciplinary; Neurodegenerative diseases; Neuropeptide Y; Neuropeptides; Organ Specificity; Respiratory quotient; Science; Science (multidisciplinary); Signal Transduction; Stat3 protein; Streptozocin; Streptozocin - adverse effects; Taurochenodeoxycholic Acid - pharmacology; Tauroursodeoxycholic acid; Thermogenesis
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-97624-6

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia. While cognitive deficits remain the major manifestation of AD, metabolic and non-cognitive abnormalities, such as alterations in food intake, body weight and energy balance are also present, both in AD patients and animal models. In this sense, the tauroursodeoxycholic acid (TUDCA) has shown beneficial effects both in reducing the central and cognitive markers of AD, as well as in attenuating the metabolic disorders associated with it. We previously demonstrated that TUDCA improves glucose homeostasis and decreases the main AD neuromarkers in the streptozotocin-induced AD mouse model (Stz). Besides that, TUDCA-treated Stz mice showed lower body weight and adiposity. Here, we investigated the actions of TUDCA involved in the regulation of body weight and adiposity in Stz mice, since the effects of TUDCA in hypothalamic appetite control and energy homeostasis have not yet been explored in an AD mice model. The TUDCA-treated mice (Stz + TUDCA) displayed lower food intake, higher energy expenditure (EE) and respiratory quotient. In addition, we observed in the hypothalamus of the Stz + TUDCA mice reduced fluorescence and gene expression of inflammatory markers, as well as normalization of the orexigenic neuropeptides AgRP and NPY expression. Moreover, leptin-induced p-JAK2 and p-STAT3 signaling in the hypothalamus of Stz + TUDCA mice was improved, accompanied by reduced acute food intake after leptin stimulation. Taken together, we demonstrate that TUDCA treatment restores energy metabolism in Stz mice, a phenomenon that is associated with reduced food intake, increased EE and improved hypothalamic leptin signaling. These findings suggest treatment with TUDCA as a promising therapeutic intervention for the control of energy homeostasis in AD individuals.